Nov 6 | Critical Conversations: The Future of American Science
Fearless: Critical Conversations on the Future of American Science
For decades, the United States has been the global leader in medical innovation, developing cures and treatments that have saved millions of lives. But is that leadership guaranteed for the future?
Join HMRI for a deliberately provocative look at the future of American medical research. We will ask the critical question: In 2050, does the U.S. still lead the world in curing disease? Or are our children traveling abroad for lifesaving treatments we failed to develop?
This President's Event Series panel discussion will convene leading voices from science, policy, and industry to explore the structural threats and opportunities facing U.S. medical innovation.
When: Thursday, November 6th, 2025 from 6 to 7 PM
Where: HMRI Engemann Family Auditorium | 686 S. Fair Oaks Ave., Pasadena, CA 91105 (Zoom option available)
Who Should Attend: Scientists, researchers, and scientific enthusiasts
Featuring Dr. Shlomo Melmed, MBChB
Featuring Dr. Shlomo Melmed, dean of the Medical Faculty at Cedars Sinai Medical Center and distinguished professor of Medicine. Melmed has been a faculty leader at Cedars‑Sinai for 45 years and has been the health system’s chief academic officer since 1998. At Cedars-Sinai, he has shepherded the highest nationally ranked systemwide programs with a sustained impact on the practice of medicine by his clinical leadership and translational endocrinology discoveries. An international authority on pituitary medicine, he has pioneered the discovery and application of novel treatments for endocrine tumors and has authored more than 400 peer-reviewed articles in prestigious journals.
Moderated by Dr. Julia Bradsher, PhD, MBA
As President & CEO of Huntington Medical Research Institutes, Julia Bradsher leads groundbreaking work in neurosciences, cardiovascular health, and aging. With more than 25 years of executive leadership - including 16 years as a CEO - she’s guided organizations through transformation, growth, and complex strategic challenges.